[Thalidomide treatment in multiple myeloma].
Hattori
Yutaka
Y
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D017322:Clinical Trials, Phase II as Topic; D003131:Combined Modality Therapy; D003546:Cysteine Endopeptidases; D003907:Dexamethasone / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000077269:Lenalidomide; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors; D009101:Multiple Myeloma / Q000188:drug therapy*; D046988:Proteasome Endopeptidase Complex; D011719:Pyrazines / Q000627:therapeutic use; D012008:Recurrence; D013792:Thalidomide / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D001897:Boronic Acids; D004791:Enzyme Inhibitors; D009097:Multienzyme Complexes; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex; D000077269:Lenalidomide